Findings: RCTSTEP-HFpEF DM trial - Semaglutide vs Placebo in Obese Diabetics with HFpEF, NEJM (2024) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=616 | length = 52 weeks) in obese type 2 diabetics (BMI 30) with HFpEF Treatment: Semaglutide titrated to 2.4 mg once weekly vs Placebo Primary outcome: Change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS
Changes in cardiometabolic risk markers from baseline to 12 months were evaluated including blood pressure, fasting glucose, HbA1c, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides
The Jorge study found that GLP-1 receptor agonists were associated with reduced progression of kidney disease in SLE patients, including those with lupus nephritis
Glutathione Research FAQs What is Glutathione
Before considering BPC-157, speak with a qualified provider who can review your medical history, symptoms, medications, treatment goals, and whether peptide therapy is appropriate for you
provides pharmaceutical-grade copper peptide powder that addresses pigmentation concerns while supporting comprehensive skin regeneration, offering hope for those seeking clearer, more radiant complexions
